Background Peptidyl-arginine deiminase enzymes have been implicated in several tumour types where expression regulates tumour cell growth and survival. We hypothesised that PAD2 may play an important role in ovarian cancer and may provide utility as an independent prognostic marker. Method Using tissue microarrays of primary ovarian cancers and compiling a comprehensive database of clinicopathological variables, the expression of PAD2 was assessed by immunohistochemistry in discovery (n=194) and validation (n=360) cohorts using a monoclonal antibody specific for PAD2. Results Kaplan-Meier analysis indicated that there was an association of PAD2 expression with overall survival in discovery (p=0.033) and validation cohorts (p=0.026). Upregulated expression of PAD2 was protective and in a multivariate model PAD2 expression remained an independent prognostic factor (p=0.029). PAD2 expression was associated with known regulators of autophagy (HMGB1 and BCL2) and immune surveillance (HLA and IFGR1). Conclusion Low PAD2 expression is an independent predictor of poor survival in ovarian cancer. PAD2 is a positive regulator of citrullination within the cell and high levels of citrullinated proteins may flag the immune system to target ovarian tumors. This work suggests that targeting citrullination pathways in ovarian cancer may represent a viable therapeutic target.
|Publication status||Published - 6 Nov 2016|
|Event||National Cancer Research Institute (NCRI) Cancer Conference - University of Birmingham, Birmingham, United Kingdom|
Duration: 6 Nov 2016 → 9 Nov 2016
|Conference||National Cancer Research Institute (NCRI) Cancer Conference|
|Period||6/11/16 → 9/11/16|
Machado, L., Moseley, P. M., Moss, R., Deen, S., Nolan, C., Spendlove, I., Ramage, J., Chan, S., & Durrant, L. G. (2016). Downregulation of the citrullinating enzyme Peptidyl-arginine deiminase type-2 in ovarian cancer indicates poor prognosis. Poster session presented at National Cancer Research Institute (NCRI) Cancer Conference, Birmingham, United Kingdom.